Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA

References

• WEINER LM: Monoconal antibody therapy of cancer. Semirr. arca (1999) 26:43–51.
   Google Scholar
• GOPAL AK, PRESS OW: Clinical applications of anti-CD20 antibodies. Lab. Clin. Med. (1999) 134:445–450.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, COLEMAN M, SCHUSTER MW et al: CD-22 directed immunotherapy of NHL with Epratuzumab results in objective responses with minimal toxicity. Cancer Biothemp. Radiopharm. (2000) 15:104.
   Google Scholar
• ECKER DJ, GRIFFEY RH: RNA as a small-molecule drug target: doubling the value of genomics. Drug Discov. Today (1999) 4:420–429.
   PubMed Web of Science ®Google Scholar
• SCHEIN CH: From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases. Nat. Biotechnol. (1997) 15:529–536.
   PubMed Web of Science ®Google Scholar
• •Review on biological roles of RNAses.
   Google Scholar
• RYBAK SM, NEWTON DL: Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp. Cell Res. (1999) 253:325–335.
   PubMed Web of Science ®Google Scholar
• •Review on therapeutic applications of RNAses.
   Google Scholar
• LELAND PA, RAINES RT: Cancer chemotherapy - ribonucleases to the rescue. Chem. Biol. (2001) 8:405–413.
   PubMed Web of Science ®Google Scholar
• LENZ GR, NASH HM, JINDAL S: Chemical ligands, genomics and drug discovery. Drug Discov. Today (2000) 5:145-156. WILSON WD, LI K: Targeting RNA with small molecules. Cum: Med. Chem. (2000) 7:73-98. Background on RNA as a molecular target.
   Google Scholar
• MOAZED S, NOLLER HF: Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature (1987) 327:389–394.
   PubMed Web of Science ®Google Scholar
• PUROHIT P, STERN S: Interactions of a small RNA with antibiotic and RNA ligands of the 30S subunit. Nature (1994) 370:659–662.
   PubMed Web of Science ®Google Scholar
• RECHT M, FOURMY D, BLANCHARD S et al.: RNA sequence determinants for aminoglycoside binding to an A-site rRNA model oligonucleotide. j Mol. Biol. (1996) 262:421–436.
   PubMed Web of Science ®Google Scholar
• MIYAGUCHI H, NARITA H, SAKAMOTO K et al.: An antibiotic-binding motif of an RNA fragment derived from the A-site-related region of Escherichia coil 16S rRNA. Nucl. Adds Res. (1996) 24:3700–3706.
   PubMed Web of Science ®Google Scholar
• FOURMY D, RECHT M, BLANCHARD S et al: Structure of the A site Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science (1996) 274:1367–1371.
   PubMed Web of Science ®Google Scholar
• AHSEN UV, DAVIES J, SCHROEDER R: Antibiotic inhibition of group I ribozyme function. Nature (1991) 353:302–303.
   PubMedGoogle Scholar
• STAGE T, HERTEL K, UHLENBECK 0: Inhibition of the hammerhead ribozyme by neomycin. RIVA (1995) 1:95–101.
   Google Scholar
• CLOUET D ORVAL B, STAGE T, UHLENBECK O: Neomycin inhibition of the hammerhead ribozyme involves ionic interactions. Biochemistry (1995) 34:11186–11190.
   PubMed Web of Science ®Google Scholar
• ROGERS J, CHANG A, AHSEN UV et al.: Inhibition of the self-cleavage reaction of the human hepatitis delta virus ribozyme by antibiotics. J. Mol Biol. (1996) 259:916–925.
   PubMed Web of Science ®Google Scholar
• WANG S, HUBER P, CUI M et at.: Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. Biochemistry (1998) 37:5549–5557.
   Google Scholar
• ZAPP M, STERN S, GREEN M: Small molecules that selectively block RNA binding of HIV-1 rev protein inhibit Rev function and viral production. Cell (1993) 74:969–978.
   PubMed Web of Science ®Google Scholar
• HERMANN T, WESTHOF E: RNA as a drug target: chemical, modelling, and evolutionary tools. Curr. Opin Biotech. (1998) 9:66–73.
   PubMed Web of Science ®Google Scholar
• •Background on RNA as a molecular target.
   Google Scholar
• HECHT SM: Bleomycin: new perspectives on the mechanism of action. j Nat. Prod. (2000) 63:158–168.
   PubMed Web of Science ®Google Scholar
• ••tRNA is shown to be a molecular target fora classical DNA damaging chemotherapeutic agent. The activity profile in the NCI-anti-cancer screen is similar to onconase.
   Google Scholar
• LIN JJ, NEWTON DL, MIKULSKI SM et al.: Characterization of the mechanism of cellular and cell free protein synthesis inhibition by an anti-tumor ribonuclease. Biochem. Biophys. Res. Commun. (1994) 204:156–162.
   PubMed Web of Science ®Google Scholar
• IORDANOV MS, RYABININA OP, WONG et al.: Molecular determinants of programmed cell death induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res. (2000) 60:1983–1994.
   PubMed Web of Science ®Google Scholar
• ••Novel mechanisms of cell death arereported to be caused by onconase induced damage to tRNA.
   Google Scholar
• DARZYNKIEWICZ Z, CARTER SP, MIKULSKI SM et al: Cytostatic and cytotoxic effects of Pannon (P-30 protein) a novel anti-cancer agent. Cell Tissue Kinet. (1988) 21:169–182.
   PubMedGoogle Scholar
• MIKULSKI SM, ARDELT W, SHOGEN K et al: Striking increase of survival of mice bearing M109 Madison Carcinoma treated with a novel protein from amphibian embryos. I Natl. Cancer hut. (1990) 82:151–153.
   PubMed Web of Science ®Google Scholar
• MIKULSKI SM, VIERA A, ARDELT W et al.: Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatickytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. Cell Tissue Kinet. (1990) 23:237–246.
   PubMedGoogle Scholar
• MIKULSKI SM, VIERA A, DARZYNKIEWICZ A et al: Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br j. Cancer (1992) 66:304–310.
   PubMed Web of Science ®Google Scholar
• MIKULSKI SM, VIERA A, SHOGEN K: In vitro synergism between a novel amphibian oocytic ribonuclease (Onconase) and tamoxifen, lovastatin and cisplatin in human OVCAR-3 ovarian carcinoma cell line. Int. J. Oncology (1992) 1:779–785.
   PubMed Web of Science ®Google Scholar
• RYBAK SM, PEARSON JW, FOGLER WF etal.: Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with Onconase, an antitumor ribonuclease. j Natl. Cancer Inst. (1996) 88:747–753.
   Google Scholar
• •Cytotoxic RNAse in clinical trials synergises with chemotherapeutics even in the presence of p-glycoprotein mediated drug resistance.
   Google Scholar
• NEWTON DL, HANSEN HJ, MIKULSKI SM et al: Potent and specific antitumor activity of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood (2001) 97:528–535.
   PubMed Web of Science ®Google Scholar
• ••Potent, specific activity without toxicity to mice bearing human lymphoma of anti-CD22 targeted RNAse.
   Google Scholar
• MIKULSKI SM, GROSSMAN AM, CARTER PW etal.: Phase 1 human clinical trial of ONCONASE (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int. j Oncol. (1993) 3:57–64.
   Google Scholar
• VASANDANI VM, WU YN, MIKULSKI SM etal.: Molecular determinants in the Plasma clearance and tissue distributiion of ribonucleases of the ribonuclease A superfamily. Cancer Res. (1996) 56:4180–4186.
   Google Scholar
• WU YN, MIKULSKI SM, ARDELT Wet al.: Cytotoxic ribonuclease: a study of the mechanism of Onconase cytotoxicity. Biol. Chem. (1993) 268:10686–10693.
   Google Scholar
• WU YN, SAXENA SK, ARDELT W etal.: A study of the intracellular routing of cytotoxic ribonucleases. _J. Biol. Chem. (1995) 270:17476–17481.
   Google Scholar
• BENHATTAR J, CEROTTINI JP, SARAGA E et al.: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer (1996) 69:190–192.
   PubMed Web of Science ®Google Scholar
• RYBAK SM, SAXENA SK, ACKERMAN EJ et al: Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. j. Biol. Chem. (1991) 266:21202–21207.
   PubMed Web of Science ®Google Scholar
• NEWTON DL, ILERCIL 0, LASKE DW etal.: Cytotoxic ribonuclease chimeras: targeted tumoricidal activity in vitro and in vivo. J. Bid. Chem. (1992) 267:19572–19578.
   Google Scholar
• JINNO H, UEDA M, OZAWA S etal.: Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines: a trial for less immunogenic chimeric toxin. Can. Chemother. Pharmacol. (1996) 38:303–308.
   Google Scholar
• JINNO H, UEDA M, OZAWA S etal.: Epidermal growth factor receptor-dependent cytotoxicity for human squamous carcinoma cell lines of a conjugate composed of human EGF and RNase 1. Life Sci. (1996) 58:1901–1908.
   Google Scholar
• UEDA M, PSARRAS K, JINNO H et al: Molecular targeting for epidermal growth factor receptor expressed on breast cancer cells by human fusion protein. Breast Cancer (1997) 4:253–255.
   PubMedGoogle Scholar
• NEWTON DL, XUE Y, OLSON KA et al.: Angiogenin single-chain immunofusions:influence of peptide linkers and spacers between fusion protein domains. Biochemistry (1996) 35:545–553.
   PubMed Web of Science ®Google Scholar
• NEWTON DL, NICHOLLS PJ, RYBAK SM et al.: Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv.,./. Biol. Chem. (1994) 269:26739–26745.
   PubMed Web of Science ®Google Scholar
• RYBAK SM, HOOGENBOOM HR, MEADE HM et al.: Humanization of immuntoxins. Proc. Nati Acad. Sd. USA (1992) 89:3165–3169.
   PubMed Web of Science ®Google Scholar
• ZEWE M, RYBAK SM, DUBEL S etal.: Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology (1997) 3:127–136.
   Google Scholar
• PSARRAS K, UEDA M, YAMAMURA T et al.: Human pancreatic RNasel -humanepidermal growth factor fusion: an entirely human immunotoxin analog with cytotoxic properties against squamous cell carcinomas. Prot. Eng. (1998) 11:1285–1292.
   PubMedGoogle Scholar
• YOON JM, HAN SH, KOWN OB et al.: Cloning and cytotoxicity of fusion proteins of EGF and angiogenin. Life Sci (1999) 64:1435–1445.
   PubMed Web of Science ®Google Scholar
• FUTAMI J, SENO M, UEDA M et al.: Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Prot. Eng. (1999) 12:1013–1019.
   PubMedGoogle Scholar
• PSARRAS K, UEDA M, TANABE Metal.: Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNasel-human IL-2 fusion. Cytokine (2000) 12:786–790.
   Google Scholar
• NEWTON DL, POLLOCK D, DITULLIO P etal.: Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice. I Immurrol. Methods (1999) 231:159–167.
   Google Scholar
• NEWTON DL, POLLOCK D, DITULLIO P etal.: Functional properties of human ribonuclease fusion proteins expressed in Escherichia coil or transgenic mice.j Int. Soc. Tumor Targ. (2000) 1:70–81.
   Google Scholar
• KAO R, DAVIES J: Molecular dissection ofmitogillin reveals that the fungal ribotoxins are a family of natural genetically engineered ribonucleases. I Biol. Chem. (1999) 274:12576–12582.
   Web of Science ®Google Scholar
• WOOL IG, BLUCK A, ENDO Y: Ribotoxin recognition of ribosomal RNA and a proposal for the mechanism of translocation. Trends Biochem. Sci. (1992) 17:266–269.
   PubMed Web of Science ®Google Scholar
• PRESS OW: Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. Cancer j Sri. Am. (1998) 4:S19–26.
   PubMed Web of Science ®Google Scholar
• •Global clinical perspective on antibody mediated treatment of lymphoma.
   Google Scholar
• WHITE C, WEAVER R, GRILLO-LOPEZ A: Antibody-targeted immunotherapy for treatment of malignancy. Ann. Rev. Med. (2001) 52:125–145.
   PubMed Web of Science ®Google Scholar
• •Global clinical perspective on antibody mediated treatment of lymphoma.
   Google Scholar
• RILEY J, SLIWKOWSKI M: CD20: a gene in search of a function. Semin. Oricol. (2000) 27:17–24.
   PubMed Web of Science ®Google Scholar
• STASHENKO P, NADLER LM, HARDY R et al.: Characterization of a human B lymphocyte-specific antigen. j Immurrol. (1980) 125:1678–1685.
   Web of Science ®Google Scholar
• GRILLO-LOPEZ A: Rituximab: an insider's historical perspective. Semi]. Oricol. (2000) 27:17–24.
   Google Scholar
• •Historical perspective on development of anti-CD20 mAb therapy (rituximab).
   Google Scholar
• MALONEY D, LILES T, CZERWINSKI D et al.: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood(1994) 84:2457–2466.
   PubMed Web of Science ®Google Scholar
• MALONEY D, GRILLO-LOPEZ A, BODKIN D et al.: IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. I Chu. One. (1997) 15:3266–3274.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ A, LINK B et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. j Chu. One. (1998) 16:2825–2833.
   PubMed Web of Science ®Google Scholar
• ••Pivotal clinical trial of rituximab.
   Google Scholar
• MCLAUGHLIN P, HAGEMEISTER FB, GRILLO-LOPEZ AJ: Rituximab in indolent lymphoma: the single-agent pivotal trials. Sem. arca. (1999) 26:79–87.
   Google Scholar
• •Subsequent analysis of pivotal rituximab clinical trial and update.
   Google Scholar
• KUNKEL L, WONG A, MANEATIS T et al.: Optimizing the use of rituximab for the treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. Sem. Oricol. (2000) 27:53–61.
   PubMed Web of Science ®Google Scholar
• PIRO LD, WHITE CA, GRILLO-LOPEZ AJ et al.: Extended rituximab (anti-CD 20monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. arca. (1999) 10:655–661.
   Google Scholar
• CZUCZMAN M, GRILLO-LOPEZ A, WHITE C etal.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.j Chu. arca. 17:268–276.
   Google Scholar
• NORDOY T, KOLSTAD A, TUCK MK et al.: Radioimmnotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Chu. Immurrol. (2001) 100:40–48.
   Google Scholar
• KELM S, PELZ A, SCHAUER R etal.: Sialoadhesin, myelin-associate glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Gun: Bic/ (1994) 4:965–972.
   Google Scholar
• NATH D, VAN DER MERWE A, KELM S et al.: The amino-terminal immunoglobulin-like domain of sialoadhesin contains the sialic acid binding site.J.Biol. Chem. (1995) 270:26184–26191.
   Google Scholar
• DOODY GM, DEMPSEY PW, FEARON DT: Activation of B lymphocytes: integrating signals from CD19, CD22 and FcyRIIbl. Cum: Opirr. Immurrol. (1996) 8:378–382.
   Google Scholar
• LI JL, SHEN GL, GHETIE MA et al.: Theepitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell Immurrol. (1989) 118:85–99.
   PubMed Web of Science ®Google Scholar
• PAWLAK-BYCZKOWSKA EJ, HANSEN HJ, DION AS et al.: Two new monoclonal antibodies, EPB-1 and EPB-2 reactive with human lymphoma. Cancer Res. (1989) 49:4568–4577.
   PubMed Web of Science ®Google Scholar
• STEIN R, BELISLE E, HANSEN HJ et al.:Epitope specificity of the anti-B-cell lymphoma monoclonal antibody, LL2. Cancer Immurrol. Immunother. (1993) 37:293–298.
   PubMed Web of Science ®Google Scholar
• JUWEID M, STADTMAUER E, HADAR G etal.: Pharmacokinetics, dosimetry, and initial therapeutic results with 1311-and 1111n 9° Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin. Can. Res. (1999) 5:3292–3303.
   Google Scholar
• JUWEID M, SHARKEY RIVI, MARKOWITZ A et al.: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. (1995) 55:5899s–5907s.
   Google Scholar
• •Description of possibilities of anti-CD22 mfisb therapy for lymphoma.
   Google Scholar
• VOSE JM, COLCHER D, GOBAR L et al.: Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leukemia Lymphoma (2000) 38:91–101.
   PubMed Web of Science ®Google Scholar
• THRUSH GR, LARK LR, CLINCHY BC et al: Immunotoxins: an update. Ann. Rev Immunol. (1996) 14:49–71.
   PubMed Web of Science ®Google Scholar
• PASTAN I: Targeted therapy of cancer with recombinant immunotoxins. Biochim. Biophys. Acta (1997) 1333:C1–C6.
   PubMed Web of Science ®Google Scholar
• SHIH LB, LU HHA, XUAN H et al.: Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int. j Cancer (1994) 56:538–545.
   PubMed Web of Science ®Google Scholar
• SHAN D, PRESS OW: Constitutive endocytosis and degradation of CD22 by human B cells. j Immunol. (1995) 154:4466–4475.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, HANSEN HJ, JONES AL et al.: Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res. (1993) 53:819–825.
   PubMed Web of Science ®Google Scholar
• MANSFIELD E, PASTAN I, FITZGERALD DJ: Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjugate Chem. (1996) 7:557–563.
   PubMed Web of Science ®Google Scholar
• MANSFIELD E, AMLOT E PASTAN I et al.: Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood (1997) 1997:2020–2026.
   Google Scholar
• GHETIE MA, RICHARDSON J, TUCKER T et al.: Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease effect on tumor cells in extranodal sites. Cancer Res. (1991) 51:5876–5880.
   PubMed Web of Science ®Google Scholar
• GHETIE MA, TUCKER K, RICHARDSON J et al.: The anti-tumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood (1992) 84:702–707.
   Google Scholar
• VAN HORSSEN E PREIJERS E VAN OOSTERHOUT YVJM et al: Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice. Int. Cancer (1996) 68:378–383.
   PubMed Web of Science ®Google Scholar
• VAN HORSSEN PJ, VAN OOSTERHOUT YVJM, EVERS S et al: Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells. Leukemia (1999) 13:241–249.
   PubMed Web of Science ®Google Scholar
• FLAVELL DJ, NOSS A, PULFORD DAF et al: Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, CD22, and CD38-Saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeflcient mice. Cancer Res. (1997) 57:4824–4829.
   PubMed Web of Science ®Google Scholar
• BOLOGNESI A, TAZZARI E OLIVIERI F etal.: Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (0M124): in vitro and in vivo studies. Br. I Haematology (1998) 101:179–188.
   Google Scholar
• CAMPANA D, JANOSSY G, BOFILL M et al: Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J. Immunol. (1985) 134:1524–1530.
   Google Scholar
• AMLOT PL, STONE MJ, CUNNINGHAM D et al: A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood(1993) 82:2624–2633.
   PubMed Web of Science ®Google Scholar
• SAUSVILLE EA, HEADLEE D, STETLER-STEVENSON M et al: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SIVIPT-dgA in patients with B-cell lymphoma: a Phase I study. Blood (1995) 85:3457–3465.
   PubMed Web of Science ®Google Scholar
• MESSMANN R, VITETTA E, HEADLEE D et al: A Phase 1 study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG- RFB4-dgA (combotox) in patients with refractory CD19 (+), CD22 (-) B cell lymphoma. Clin. Can. Res. (2000) 6:1302–1313.
   PubMed Web of Science ®Google Scholar
• KREITMAN R, STETLER-STEVENSON M, WILSON W et al: Recombinant anti-CD22 immunotoxin BL22 induces complete remissions in purine analog-resistant hairy cell leukemia, associated with expansions of cytotoxic T-cells. Proc Am. Assoc. Cancer Res. (2001) 42:700.
   Google Scholar
• KREITMAN RJ, WILSON WH, BERERON K etal.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. (2001) 345:241–247.
   Google Scholar
• RYBAK SM, YOULE RJ: Clinical use of immunotoxins: monoclonal antibodies conjugated to protein toxins. Immunol. Allergy CM]. N. Am. (1991) 11:359–380.
   Web of Science ®Google Scholar
• VITETTA ES, THORPE PE, UHR JW: Immunotoxins: magic bullets or misguided missiles. Fiends Phannacol.Sci. (1993) 14:148–154.
   PubMed Web of Science ®Google Scholar
• MIKULSKI SM: Phase II trial of Onconase in patients with advanced malignant mesothelioma: analysis of survival. Fifth International Meeting on Ribenucleases (1999) Warrenton, VA, USA
   Google Scholar
• CHEN SL, LE SY, NEWTON DL et al: A gender specific mRNA encoding a cytotoxic ribonuclease contains a 3 UTR of unusual length and structure. Nucl. Acids Res. (2000) 28:2375–2382.
   PubMed Web of Science ®Google Scholar
• SAXENA SK, RYBAK SM, WINKLER G etal.: Comparison of RNases and toxins upon injection into Xenopus oocytes. Biol. Chem. (1991) 266:21208–21214.
   Google Scholar
• VITETTA ES, STONE M, AMLOT P et al:Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. (1991) 51(15):4052–4058.
   PubMed Web of Science ®Google Scholar